Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) - ...

"We are pleased to welcome Dalia to the company in advance of the upcoming readout for our Phase 3 EFZO-FIT™ study of ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...

Earlier this year, the tiny rocket company that wants to grow up to be SpaceX someday told NASA that, if it's agreeable, ...

Tuesday’s 10 Worst Performers. In this article, we are going to take a look at where Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stands against other Tuesday’s worst performers. Wall Street finished ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the stock right now. Should you?

A dance showcase titled "Her Story; Her Comeback" will take place at the Brockton VFW on March 30. Tickets are available.

Signaturefd LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 357.2% during the 4th ...

Swiss National Bank grew its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 0.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...

Merck & Co. Inc. is making a high-stakes move in the cardiovascular drug market, announcing on Tuesday an exclusive licensing ...

X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of ...